Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and metformin extended-release 2000mg.
This medicine is generally administered once daily with the evening meal.
The maximum dose of this medicine is dapagliflozin 10mg/metformin extended-release 2000mg once daily, administered as two 5mg/1000mg tablets.
Patients who have not previously received antidiabetic drug therapy and for whom adequate glycemic control cannot be achieved with monotherapy:
When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be titrated gradually to reduce the gastrointestinal adverse effects of metformin.
In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the existing doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately.
The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering agents. Because any change may cause alterations in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring.
This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this medicine may be excreted in the feces as a soft, hydrated mass resembling a tablet.
Renal impairment
No dose adjustment is required in patients with mild renal impairment.
For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2.
If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months.
Older adults
Because metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient subsection).
Improves glycemic control in adults with type 2 diabetes mellitus
View approved original textHide original text
This medication is administered in combination with dietary and exercise therapy to improve blood sugar control in adult patients with type 2 diabetes using Dapagliflozin and Metformin. It can be used in patients with insufficient blood sugar control, particularly those with cardiovascular disease or risk factors. However, in such cases, the effects of Dapagliflozin on the occurrence of cardiovascular events should refer to expert clinical trial information. This drug aids in safe blood sugar management and is effectively used in the treatment of diabetes.
How to take
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and metformin extended-release 2000mg.
This medicine is generally administered once daily with the evening meal.
The maximum dose of this medicine is dapagliflozin 10mg/metformin extended-release 2000mg once daily, administered as two 5mg/1000mg tablets.
Patients who have not previously received antidiabetic drug therapy and for whom adequate glycemic control cannot be achieved with monotherapy:
When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be titrated gradually to reduce the gastrointestinal adverse effects of metformin.
In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the existing doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately.
The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering agents. Because any change may cause alterations in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring.
This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this medicine may be excreted in the feces as a soft, hydrated mass resembling a tablet.
Renal impairment
No dose adjustment is required in patients with mild renal impairment.
For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2.
If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months.
Older adults
Because metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient subsection).
Precautions
This medication is used for the treatment of diabetes and should not be used in patients with poor kidney function or specific health conditions.
It can rarely cause a dangerous condition called lactic acidosis, so immediate consultation with healthcare professionals is needed if symptoms appear.
When used with insulin or other diabetes medications, hypoglycemia may occur, thus careful monitoring of blood sugar levels is necessary.
Patients with reduced kidney function, those who are dehydrated, or those with low blood pressure should be particularly cautious when using this medication, and regular checks on kidney function and blood pressure are required.
Genital or urinary tract infections may occur, and prompt treatment is necessary if such symptoms arise.
This medication is not recommended for use in pregnant or nursing women, and its use should cease if pregnancy is confirmed.
Elderly patients have an increased risk of reduced kidney function and fluid volume depletion, requiring careful monitoring and dosage adjustment.
Excessive alcohol consumption should be avoided during treatment, and potential interactions with other drugs should be discussed with healthcare professionals.
In case of overdose, appropriate medical treatment should be sought immediately.
While taking this medication, caution is advised when driving or operating machinery due to possible dizziness.
Lastly, this medication should be kept out of the reach of children and stored in its original container.
Side effects
Severe lactic acidosis
severe hypoglycemia
vulvovaginitis
balanitis
genital infection
urinary tract infection
fungal infection
hypoglycemia
decreased fluid volume
thirst
Show 84 moreCollapse
diabetic ketoacidosis
dizziness
constipation
dry mouth
lower back pain
dysuria
polyuria
nocturia
vulvar pruritus
genital pruritus
increased hematocrit
decreased renal creatinine clearance
dyslipidemia
increased serum creatinine
increased blood urea
weight loss
ketoacidosis
urosepsis
pyelonephritis
acute kidney injury
renal dysfunction
rash
diarrhea
nausea
vomiting
decreased vitamin B12
Guillain-Barré syndrome
bacterial pneumonia
sialadenitis
tendinitis
chest pain
thermal burn
wrist fracture
gastrointestinal stromal tumor
lung malignant neoplasm
uterine fibroids
atrial fibrillation
acute cholecystitis
upper abdominal pain
dyspepsia
abdominal discomfort
abdominal pain
gastric ulcer
irritable bowel syndrome
salivary gland mass
toothache
headache
facial paralysis
peripheral neuropathy
sensory disturbance
drowsiness
tremor
nasopharyngitis
pharyngitis
adenoviral conjunctivitis
shingles
pneumonia
rhinitis
increased alanine aminotransferase
increased blood sugar
arthralgia
myalgia
myofascial pain syndrome
osteoarthritis
osteochondritis
limb pain
periarticular inflammation
tendinitis
trigger finger
weakness
fatigue
peripheral edema
swelling
pain
vitamin D deficiency
hyperglycemia
urethral syndrome
cough
hyperventilation
pruritus
palpitations
insomnia
type 2a hyperlipidemia
sensorineural hearing loss
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a sealed container to protect it from air and moisture. It is important to maintain storage temperature between 1 and 30 degrees Celsius.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.